62311669317: Difference between revisions
From Verified Handles
62311669317
(Alexion Pharmaceuticals) |
(AB-V1) |
||
| (One intermediate revision by one other user not shown) | |||
| Line 1: | Line 1: | ||
{{DISPLAYTITLE:Alexion Pharmaceuticals}} | {{DISPLAYTITLE:Alexion Pharmaceuticals}} | ||
Alexion Pharmaceuticals | Alexion Pharmaceuticals, a subsidiary of AstraZeneca, is an American pharmaceutical company headquartered in Boston, Massachusetts that specializes in orphan drugs to treat rare diseases. | ||
{| | Its products include eculizumab (Soliris) with $4.064 billion in 2020 revenues and ravulizumab (Ultomiris) with $1.076 billion in 2020 revenues, both used to treat the rare disorders of atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH); asfotase alfa (Strensiq) with $731 million in 2020 revenues, used to treat hypophosphatasia; sebelipase alfa (Kanuma) with $117 million in 2020 revenues, used to treat lysosomal acid lipase deficiency, and andexanet alfa (Andexxa) with $78 million in 2020 revenues, used to stop life threatening or uncontrollable bleeding in people who are taking rivaroxaban or apixaban.With costs that can reach as much as $2 million per year, the drugs manufactured by Alexion are some of the most expensive drugs worldwide.<small> from [https://en.wikipedia.org/wiki/Alexion_Pharmaceuticals Wikipedia]</small> | ||
{{SF| | |||
{{Twt|AlexionPharma}} | {{Twt|AlexionPharma}} | ||
{{Wb|https://alexion.com/| | {{Wb|https://alexion.com/|alexion.com}} | ||
{{Yt|UClgBSounH8P9Lo22uaaZ0gw|Alexion Pharmaceuticals}} | {{Yt|UClgBSounH8P9Lo22uaaZ0gw|Alexion Pharmaceuticals, Inc.}} | ||
|} | }} | ||
{{IDF| | |||
{{Isni|0000000404080730}} | |||
}} | |||
{{VHID|62311669317}}{{#subtitle: <big>American company</big>}} | |||
{{#subtitle: <big>American company</big>}} | |||
Latest revision as of 17:17, 27 February 2022
Alexion Pharmaceuticals, a subsidiary of AstraZeneca, is an American pharmaceutical company headquartered in Boston, Massachusetts that specializes in orphan drugs to treat rare diseases. Its products include eculizumab (Soliris) with $4.064 billion in 2020 revenues and ravulizumab (Ultomiris) with $1.076 billion in 2020 revenues, both used to treat the rare disorders of atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH); asfotase alfa (Strensiq) with $731 million in 2020 revenues, used to treat hypophosphatasia; sebelipase alfa (Kanuma) with $117 million in 2020 revenues, used to treat lysosomal acid lipase deficiency, and andexanet alfa (Andexxa) with $78 million in 2020 revenues, used to stop life threatening or uncontrollable bleeding in people who are taking rivaroxaban or apixaban.With costs that can reach as much as $2 million per year, the drugs manufactured by Alexion are some of the most expensive drugs worldwide. from Wikipedia
| Icon | Service | Username | |
|---|---|---|---|
 |
@AlexionPharma |  | |
 |
Website | alexion.com | |
 |
YouTube | @Alexion Pharmaceuticals, Inc. | |
Additional identifiers
These are provided for reference and have been verified to be accurate.
| Icon | Database | Identifier | |
|---|---|---|---|
 |
ISNI | 0000000404080730 | |